DK1107737T3 - Mikropartikler til anvendelse ved nålelös injektion - Google Patents

Mikropartikler til anvendelse ved nålelös injektion

Info

Publication number
DK1107737T3
DK1107737T3 DK99943130T DK99943130T DK1107737T3 DK 1107737 T3 DK1107737 T3 DK 1107737T3 DK 99943130 T DK99943130 T DK 99943130T DK 99943130 T DK99943130 T DK 99943130T DK 1107737 T3 DK1107737 T3 DK 1107737T3
Authority
DK
Denmark
Prior art keywords
microparticles
needless injection
therapeutic agent
needless
agent
Prior art date
Application number
DK99943130T
Other languages
Danish (da)
English (en)
Inventor
Nicholas David Osborne
Original Assignee
Quadrant Drug Delivery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10838317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1107737(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Quadrant Drug Delivery Ltd filed Critical Quadrant Drug Delivery Ltd
Application granted granted Critical
Publication of DK1107737T3 publication Critical patent/DK1107737T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1658Proteins, e.g. albumin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Disintegrating Or Milling (AREA)
  • Glanulating (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
DK99943130T 1998-09-03 1999-09-03 Mikropartikler til anvendelse ved nålelös injektion DK1107737T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9819272.7A GB9819272D0 (en) 1998-09-03 1998-09-03 Microparticles

Publications (1)

Publication Number Publication Date
DK1107737T3 true DK1107737T3 (da) 2004-08-02

Family

ID=10838317

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99943130T DK1107737T3 (da) 1998-09-03 1999-09-03 Mikropartikler til anvendelse ved nålelös injektion

Country Status (15)

Country Link
US (3) US20020197325A1 (de)
EP (2) EP1410792B1 (de)
JP (2) JP2002524411A (de)
CN (1) CN1315854A (de)
AT (2) ATE386507T1 (de)
AU (1) AU5640799A (de)
BR (1) BR9913456A (de)
CA (1) CA2342206C (de)
DE (2) DE69916856T2 (de)
DK (1) DK1107737T3 (de)
ES (2) ES2223181T3 (de)
GB (1) GB9819272D0 (de)
IL (1) IL141323A0 (de)
MX (1) MXPA01002323A (de)
WO (1) WO2000013668A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002538195A (ja) * 1999-03-08 2002-11-12 パウダージェクト リサーチ リミテッド 生物活性化合物の持続放出用の無針注射器を使用する微粒子製剤の送達
US8771740B2 (en) * 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
DE10045521A1 (de) 2000-03-31 2001-10-04 Roche Diagnostics Gmbh Nukleinsäureamplifikationen
WO2002058670A1 (en) * 2001-01-25 2002-08-01 Euroceltique S.A. Local anesthetic, and method of use
WO2002100380A1 (en) * 2001-06-08 2002-12-19 Powderject Vaccines, Inc. Production of hard, dense particles
WO2003037303A1 (en) 2001-11-01 2003-05-08 Nektar Therapeutics Spray drying methods and compositions thereof
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
JP2007508240A (ja) * 2003-07-22 2007-04-05 バクスター・インターナショナル・インコーポレイテッド 低分子量有機分子の小球状粒子ならびにその調製方法および使用方法
JP4210231B2 (ja) * 2004-03-25 2009-01-14 株式会社資生堂 皮膚のシワを改善する美容方法及びシワ改善具
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
CA2603031A1 (en) * 2005-03-31 2006-10-05 Rafael Armament Development Authority Ltd. Apparatus for treating particles and liquids by ultrasound
CN101272848B (zh) * 2005-07-28 2013-03-13 Isp投资有限公司 改进喷雾干燥的粉末和颗粒材料性质的方法,以及由此生产的产品
AU2007208998A1 (en) * 2006-01-27 2007-08-02 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A method of producing porous microparticles
MX2009001226A (es) 2006-08-04 2009-03-20 Baxter Int Composicion basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nuevo inicio.
DE202006018609U1 (de) 2006-08-29 2007-05-16 Euro-Celtique S.A. Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
US8613946B2 (en) * 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
EP2125938A2 (de) * 2007-01-26 2009-12-02 Isp Investments Inc. Verfahren zur herstellung einer formulierung für sprühgetrocknete produkte
ITMI20080807A1 (it) 2008-05-05 2009-11-06 Antibioticos Spa Procedimento per la preparazione di tigeciclina in forma amorfa
US8323685B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
CN101732259B (zh) * 2009-12-29 2012-08-29 广东药学院 壳聚糖微米粒及其制备方法和应用
US9135998B2 (en) * 2010-11-09 2015-09-15 Micron Technology, Inc. Sense operation flags in a memory device
EP2898894A1 (de) 2014-01-27 2015-07-29 LTS LOHMANN Therapie-Systeme AG Nano-in-mikro-Teilchen zur intradermalen Verabreichung
CN111886031B (zh) * 2018-01-10 2022-10-14 G2G生物公司 含胶原蛋白肽的聚己内酯微球填充物及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3937668A (en) * 1970-07-15 1976-02-10 Ilse Zolle Method for incorporating substances into protein microspheres
CA1077842A (en) * 1975-10-09 1980-05-20 Minnesota Mining And Manufacturing Company Albumin medicament carrier system
US4247406A (en) * 1979-04-23 1981-01-27 Widder Kenneth J Intravascularly-administrable, magnetically-localizable biodegradable carrier
US4349530A (en) * 1980-12-11 1982-09-14 The Ohio State University Implants, microbeads, microcapsules, preparation thereof and method of administering a biologically-active substance to an animal
US4357254A (en) * 1981-01-12 1982-11-02 Chemical Sciences, Inc. Cleaning composition
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
FR2663224B1 (fr) * 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
WO1994008576A1 (en) * 1992-10-16 1994-04-28 Glaxo Group Limited Taste-masking compositions of ranitidine
TW360548B (en) * 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
US5899880A (en) * 1994-04-08 1999-05-04 Powderject Research Limited Needleless syringe using supersonic gas flow for particle delivery
ATE177944T1 (de) * 1994-06-15 1999-04-15 Dumex Ltd As Pellets
IT1274879B (it) * 1994-08-03 1997-07-25 Saitec Srl Apparecchio e metodo per preparare forme farmaceutiche solide a rilascio controllato del principio attivo.
GB9502879D0 (en) * 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
KR100201352B1 (ko) * 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
US5922253A (en) * 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
US6117449A (en) * 1996-03-22 2000-09-12 Bio-Sphere Technology, Inc. Method for inducing a systemic immune response to a hepatitis antigen
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
GB9612629D0 (en) * 1996-06-17 1996-08-21 Oxford Biosciences Ltd Method for providing dense particle compositions for use in transdermal particle delivery

Also Published As

Publication number Publication date
ATE386507T1 (de) 2008-03-15
EP1107737A1 (de) 2001-06-20
DE69916856T2 (de) 2005-04-21
BR9913456A (pt) 2001-07-24
IL141323A0 (en) 2002-03-10
US20050002870A1 (en) 2005-01-06
US20070026081A1 (en) 2007-02-01
DE69916856D1 (de) 2004-06-03
CN1315854A (zh) 2001-10-03
EP1410792B1 (de) 2008-02-20
EP1410792A1 (de) 2004-04-21
US20020197325A1 (en) 2002-12-26
EP1410792A8 (de) 2004-12-29
CA2342206A1 (en) 2000-03-16
ES2301929T3 (es) 2008-07-01
ATE265204T1 (de) 2004-05-15
MXPA01002323A (es) 2002-05-08
AU5640799A (en) 2000-03-27
JP2002524411A (ja) 2002-08-06
EP1107737B1 (de) 2004-04-28
WO2000013668A1 (en) 2000-03-16
GB9819272D0 (en) 1998-10-28
DE69938201D1 (de) 2008-04-03
JP2006096755A (ja) 2006-04-13
DE69938201T2 (de) 2009-02-12
CA2342206C (en) 2006-12-12
ES2223181T3 (es) 2005-02-16

Similar Documents

Publication Publication Date Title
DK1107737T3 (da) Mikropartikler til anvendelse ved nålelös injektion
HUT76258A (en) Compositions comprising dna damaging agents and p53, and methods for uses thereof
CY1107351T1 (el) Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
HK1048986A1 (en) 2'-Substituted 1,1'-iphenyl-2-carbonamides, methodfor the production thereof, use thereof as medicament and pharmaceutical preparations containing said compounds.
MX9603925A (es) Combinaciones de anticoagulantes y proteinas activas tromboliticamente, y usos de las mismas.
NO986089D0 (no) Metoder og preparater for behandling av tumorer, tumorrelaterte sykdommer o
ID30116A (id) Turunan-turunan piridopiranoazepin, pembuatannya dan penggunaan terapinya
EP1123414A4 (de) Antisense modulation der expression von integrin alpha 4
NZ330360A (en) 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
ITRM930291A0 (it) Procedimento per la preparazione di biopolimeri iodurati con attivita'disinfettante e cicatrizzante, e biopolimeri iodurati cosi' ottenuti.
MD990258A (en) Method of treatment of the acute viral hepatitis B
ATE271852T1 (de) Verbesserte inhalationspräparate
FR2792318B1 (fr) Derives d'indazole, leur preparation et leur application en therapeutique
HU913267D0 (en) Process for the production of 1-(3,4-dihydro-2-oxo-1h-kinoline-6-yl)-2-(4-)2-phenyl-ethyl-(piperidine-1-yl)-ethanole and ethanone, and of medical preparations containing them as active agents
BG66081B1 (bg) Състави, съдържащи модафинилни съединения
BG105204A (en) Salts of paroxetine
IL148980A0 (en) An antibody to human tissue factor and experimental animals having inserted cells with the gene encoding human tissue factor
IT1285158B1 (it) Polipeptidi solubili con l'attivita' di serino-proteasi di ns3 del virus dell'epatite c, e procedimento per la loro preparazione e il
Lisanby et al. ECT and TMS: past, present, and future.
DE60010230D1 (de) Pharmazeutische zusammensetzung von hydrophob modifizierten hedgehog-proteinen und deren verwendung
DE69113049D1 (de) Varianten des gewebeplasminogenaktivators mit vermindertem abbau.
HK1027825A1 (en) Use of arylguanidinium xanthogenates as vulcanization accelerators and process for the production thereof.
RU2000112951A (ru) Способ лечения гифемы
RU99107944A (ru) Лечебное средство прямого антикоагулянтного и фибринолитического действия